Navigation Links
Pearl Therapeutics Secures $8 Million in Debt Financing
Date:2/24/2009

REDWOOD CITY, Calif., Feb. 24 /PRNewswire/ -- Pearl Therapeutics announced today that it has secured $8 million in venture debt financing. Oxford Finance Corporation and Silicon Valley Bank, a member company of SVB Financial Group (Nasdaq: SIVB), provided the capital which will be drawn in two tranches.

"We are very pleased to be working with Oxford and SVB. They are experienced and committed lenders with strong records of success evaluating risk and enabling development stage companies, particularly in the life science sector," said Adrian Smith, President and Co-founder, Pearl Therapeutics. "Our ability to secure this credit facility in today's tough economic environment speaks to the company's performance and demonstrates the confidence our lenders have in Pearl's future."

The funds will supplement the $33.5MM in equity financing Pearl has secured to date, and will be used for general growth purposes as Pearl advances development of its expanding pipeline of products.

"We are very impressed with Pearl's management team, promising products, and technology that will treat and prevent chronic respiratory diseases," said J. Alden Philbrick, President and Chief Executive Officer of Oxford Finance Corporation. "We look forward to supporting the company's progress toward achieving a leadership role in the respiratory space."

"Pearl is developing cutting edge therapeutics to address some of the most serious respiratory diseases," said Mercy Forde of Silicon Valley Bank. "SVB is proud to provide Pearl with financial resources it needs to continue to be successful and grow."

About Pearl Therapeutics, Inc.

Pearl is developing a portfolio of meaningfully differentiated products to treat respiratory diseases including COPD and asthma. Using its proprietary par
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
2. MUSCs Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
3. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
4. String of fullerene pearls
5. Pearl Therapeutics Raises $15.5 Million in Private Financing
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Amicus Therapeutics Announces Change to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... granted to German life sciences entrepreneurs with a ... of biotechnology (collectively, the "Optionee"), an option to ... vaccine technology (the "Technology"), including AEZS-120, the most ... ready to enter a Phase 1 clinical trial. ...
(Date:7/28/2015)... and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ ... announced its financial results for the second quarter ... grew nearly 300% as compared to the second ... launched," said Roger Jeffs, Ph.D., United Therapeutics, President ... sales was due to an increase in the ...
(Date:7/28/2015)... NESS ZIONA, Israel ... CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company ... repair products, today announced that Shomrat Shurtz has ... September 20, 2015.      (Photo: ... brings over 25 years of experience in marketing, ...
(Date:7/28/2015)... , July 28, 2015  Faced with increasing ... are palliative rather than symptomatic, the global healthcare ... existing therapies capable of curing or significantly changing ... starting to look towards regenerative medicine as a ... new paradigm in human health with the potential ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... LLC announced today that the first patient has ... support a new fixed-dose combination (FDC) therapy for ... known as 572-Trii, will combine the investigational integrase ... reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC). ...
... could jumpstart the promising field of cell therapy, in which ... of diseases and tissue defects, researchers at Brigham and Women,s ... the key challenges associated with the procedure: control of the ... reported in the journal Biomaterials on January 26, ...
... has become a standard tool in the search for ... disaster, but until now there has been very little ... policy challenges associated with this new use of genetic ... National Institutes of Health (NIH) has awarded Carnegie ...
Cached Biology Technology:Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 2Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 3Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 4Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 5Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 6Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 7Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 2CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 4
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... mice responsible for repairing DNA strands damaged by oxidation ... that such stress contributes to the development of cancer. ... DNA Repair by researchers at the National Institute ... University (OHSU) and the New York University School of ...
... measure organic contaminants in human body fluids, the National ... four new Standard Reference Materials (SRMs) available for purchase. ... and Prevention (CDC), the human milk and serum SRMs ... pesticides, commonly found in the U.S. population. Scientists at ...
... Netherlands: For the first time, researchers have been able ... of IVF treatment in blood. Dr. Cathy Allen, from the ... the European Society of Human Reproduction and Embryology today (Wednesday ... works for some patients but not for others. Previous ...
Cached Biology News:Genetically engineered mice yield clues to 'knocking out' cancer 2NIST issues human milk and blood serum SRMs for contaminant measurements 2Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3